Purpose: To assess the efficacy and safety of Ranibizumab in the treatment of choroidal neovascularization (CNV) caused by pathologic myopia (PM). Design: Prospective, multicenter, interventional case series. Methods: 40 of 39 consecutive patients with PM and CNV were treated with “on-demand” intravitreal injection of ranibizumab 0.5 mg. Final best-corrected VA (BCVA) and its change from baseline were the main outcome measures. Changes in Optical Coherence Tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results: Mean age was 53 ± 13 years, mean refractive error -13.5 ± 6.5 diopters. Median follow-up was 13.3 ± 2 months (range 12 – 18). Fifteen eyes (37.5%) had previously been treated with photodynamic therapy (PDT). The mean baseline logMAR BCVA (ETDRS vision chart) was 0.68 ± 0.34 (Snellen equivalent 20/131) and 21 ± 16 letters. The final mean logMAR BCVA was 0.27 ± 0.2 (p 0.008) (20/42) and 40.5 ± 14 letters (p 0.01). Mean final VA improved in 82.5% of patients, in 60% by 3 or more lines,(median number of lines gained 2.9). Even six out of seven cases of low vision (≤ 1.1 LogMAR) at the final examination improved vision. Mean OCT CRT reduced from 218±70 μm to 175±46 μm (p 0.02). Age and previous PDT did not influence results (p›0,05). The mean number of injection was 2.8 ± 1.2 (range 1-6). No ocular or systemic side effects were observed. Conclusion: Ranibizumab was an effective treatment for stabilizing and improving vision in 92.5 % of myopic CNV in a long term follow-up with a low number of injections.

Vadalà, M., Pece, A., Cipolla, S., Monteleone, C., Fasolino, G., Casuccio, A., et al. (2011). Is Ranibizumab effective in stopping loss of vision secondary to Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study. BRITISH JOURNAL OF OPHTHALMOLOGY, 95(5), 657-661 [10.1136/bjo.2009.174243].

Is Ranibizumab effective in stopping loss of vision secondary to Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study.

VADALA', Maria;CASUCCIO, Alessandra;CILLINO, Salvatore
2011

Abstract

Purpose: To assess the efficacy and safety of Ranibizumab in the treatment of choroidal neovascularization (CNV) caused by pathologic myopia (PM). Design: Prospective, multicenter, interventional case series. Methods: 40 of 39 consecutive patients with PM and CNV were treated with “on-demand” intravitreal injection of ranibizumab 0.5 mg. Final best-corrected VA (BCVA) and its change from baseline were the main outcome measures. Changes in Optical Coherence Tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results: Mean age was 53 ± 13 years, mean refractive error -13.5 ± 6.5 diopters. Median follow-up was 13.3 ± 2 months (range 12 – 18). Fifteen eyes (37.5%) had previously been treated with photodynamic therapy (PDT). The mean baseline logMAR BCVA (ETDRS vision chart) was 0.68 ± 0.34 (Snellen equivalent 20/131) and 21 ± 16 letters. The final mean logMAR BCVA was 0.27 ± 0.2 (p 0.008) (20/42) and 40.5 ± 14 letters (p 0.01). Mean final VA improved in 82.5% of patients, in 60% by 3 or more lines,(median number of lines gained 2.9). Even six out of seven cases of low vision (≤ 1.1 LogMAR) at the final examination improved vision. Mean OCT CRT reduced from 218±70 μm to 175±46 μm (p 0.02). Age and previous PDT did not influence results (p›0,05). The mean number of injection was 2.8 ± 1.2 (range 1-6). No ocular or systemic side effects were observed. Conclusion: Ranibizumab was an effective treatment for stabilizing and improving vision in 92.5 % of myopic CNV in a long term follow-up with a low number of injections.
Settore MED/30 - Malattie Apparato Visivo
Vadalà, M., Pece, A., Cipolla, S., Monteleone, C., Fasolino, G., Casuccio, A., et al. (2011). Is Ranibizumab effective in stopping loss of vision secondary to Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study. BRITISH JOURNAL OF OPHTHALMOLOGY, 95(5), 657-661 [10.1136/bjo.2009.174243].
File in questo prodotto:
File Dimensione Formato  
Ranibizumab in myopia.pdf

accesso aperto

Descrizione: Articolo full text
Dimensione 302.4 kB
Formato Adobe PDF
302.4 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/75165
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 38
social impact